Published in Br J Clin Pharmacol on March 01, 1998
Modeling endotoxin-induced systemic inflammation using an indirect response approach. Math Biosci (2008) 1.13
Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response. Br J Clin Pharmacol (2015) 1.07
Integrated cellular bone homeostasis model for denosumab pharmacodynamics in multiple myeloma patients. J Pharmacol Exp Ther (2008) 1.05
Understanding the time course of pharmacological effect: a PKPD approach. Br J Clin Pharmacol (2011) 0.91
Multiscale model for the assessment of autonomic dysfunction in human endotoxemia. Physiol Genomics (2010) 0.89
Discovery and characterization of LY2784544, a small-molecule tyrosine kinase inhibitor of JAK2V617F. Blood Cancer J (2013) 0.84
PKPD modelling of the interrelationship between mean arterial BP, cardiac output and total peripheral resistance in conscious rats. Br J Pharmacol (2013) 0.83
Understanding the hysteresis loop conundrum in pharmacokinetic/pharmacodynamic relationships. J Pharm Pharm Sci (2014) 0.82
D-optimal designs for parameter estimation for indirect pharmacodynamic response models. J Pharmacokinet Pharmacodyn (2009) 0.80
Intratumoral modeling of gefitinib pharmacokinetics and pharmacodynamics in an orthotopic mouse model of glioblastoma. Cancer Res (2013) 0.80
Mechanism-based pharmacodynamic modeling. Methods Mol Biol (2012) 0.79
Simulation of tumor-induced angiogenesis and its response to anti-angiogenic drug treatment: mode of drug delivery and clearance rate dependencies. J Cancer Res Clin Oncol (2003) 0.78
PK-PD modeling of individual lesion FDG-PET response to predict overall survival in patients with sunitinib-treated gastrointestinal stromal tumor. CPT Pharmacometrics Syst Pharmacol (2016) 0.77
A Tutorial on RxODE: Simulating Differential Equation Pharmacometric Models in R. CPT Pharmacometrics Syst Pharmacol (2015) 0.77
The role of the hypothalamic-pituitary-adrenal axis in modulating seasonal changes in immunity. Physiol Genomics (2016) 0.76
Mathematical modeling of the circadian dynamics of the neuroendocrine-immune network in experimentally induced arthritis. Am J Physiol Endocrinol Metab (2016) 0.76
From an indirect response pharmacodynamic model towards a secondary signal model of dose-response relationship between exercise training and physical performance. Sci Rep (2017) 0.75
Pharmacokinetics and pharmacodynamics of anti-BR3 monoclonal antibody in mice. Pharm Res (2012) 0.75
NC-6004 Phase I study in combination with gemcitabine for advanced solid tumors and population PK/PD analysis. Cancer Chemother Pharmacol (2017) 0.75
Understanding Physiology in the Continuum: Integration of Information from Multiple -Omics Levels. Front Pharmacol (2017) 0.75
Pharmacokinetic and pharmacodynamic characterization of a novel formulation containing co-formulated interferons alpha-2b and gamma in healthy male volunteers. BMC Pharmacol Toxicol (2016) 0.75
Bringing Model-Based Prediction to Oncology Clinical Practice: A Review of Pharmacometrics Principles and Applications. Oncologist (2015) 0.75
Applications of quantitative pharmacodynamic effect markers in drug target identification and therapy development. Anticancer Res (2007) 0.75
Model Linking Plasma and Intracellular Tenofovir/Emtricitabine with Deoxynucleoside Triphosphates. PLoS One (2016) 0.75
Deterministic identifiability of population pharmacokinetic and pharmacokinetic-pharmacodynamic models. J Pharmacokinet Pharmacodyn (2017) 0.75
Pharmacometric modeling of liver metastases' diameter, volume and density and their relation to clinical outcome in imatinib-treated GIST patients. CPT Pharmacometrics Syst Pharmacol (2017) 0.75
Pharmacokinetic-pharmacodynamic modeling of the antihypertensive interaction between azilsartan medoxomil and chlorthalidone in spontaneously hypertensive rats. Naunyn Schmiedebergs Arch Pharmacol (2017) 0.75
Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther (1979) 5.13
Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm (1993) 3.96
Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther (1994) 2.39
Kinetics of pharmacologic effects in man: the anticoagulant action of warfarin. Clin Pharmacol Ther (1969) 1.50
The time course of delivery of furosemide into urine: an independent determinant of overall response. Kidney Int (1982) 1.43
Characterization of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm (1996) 1.38
Microbial pharmacodynamics of piperacillin in neutropenic mice of systematic infection due to Pseudomonas aeruginosa. J Pharmacokinet Biopharm (1988) 1.32
Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. J Pharm Sci (1971) 1.19
Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther (1993) 1.10
Pharmacoimmunodynamics of methylprednisolone: trafficking of helper T lymphocytes. J Pharmacokinet Biopharm (1992) 1.07
Pharmacodynamic modeling of furosemide tolerance after multiple intravenous administration. Clin Pharmacol Ther (1996) 1.04
Pharmacodynamic model for joint exogenous and endogenous corticosteroid suppression of lymphocyte trafficking. J Pharmacokinet Biopharm (1994) 1.02
Use of an indirect pharmacodynamic stimulation model of MX protein induction to compare in vivo activity of interferon alfa-2a and a polyethylene glycol-modified derivative in healthy subjects. Clin Pharmacol Ther (1996) 1.01
Mathematical model for in vivo pharmacodynamics integrating fluctuation of the response: application to the prolactin suppressant effect of the dopaminomimetic drug DCN 203-922. J Pharmacokinet Biopharm (1991) 0.99
Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. J Clin Pharmacol (1996) 0.98
Convergence of direct and indirect pharmacodynamic response models. J Pharmacokinet Biopharm (1995) 0.97
Corticosteroid pharmacodynamic modeling: osteocalcin suppression by prednisolone. Pharm Res (1992) 0.97
Third-generation model for corticosteroid pharmacodynamics: roles of glucocorticoid receptor mRNA and tyrosine aminotransferase mRNA in rat liver. J Pharmacokinet Biopharm (1995) 0.96
Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects. J Pharmacol Exp Ther (1995) 0.92
Pharmacodynamic considerations in the use of diuretics. Annu Rev Pharmacol Toxicol (1983) 0.90
Intravenous nizatidine kinetics and acid suppression. Clin Pharmacol Ther (1985) 0.88
A model eliciting transient responses. Am J Physiol (1984) 0.84
Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes. Clin Pharmacol Ther (1995) 0.83
Pharmacodynamic modeling of finasteride, a 5 alpha-reductase inhibitor. Pharmacotherapy (1995) 0.82
Pharmacodynamic modeling of nonsteroidal anti-inflammatory drugs: antipyretic effect of ibuprofen. Clin Pharmacol Ther (1994) 0.81
LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed (1983) 4.02
Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm (1993) 3.96
General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn (2001) 3.21
Gentamicin disposition and tissue accumulation on multiple dosing. J Pharmacokinet Biopharm (1977) 1.90
Tissue persistence of gentamicin in man. JAMA (1977) 1.79
Ampicillin and hetacillin pharmacokinetics in normal and anephric subjects. Clin Pharmacol Ther (1973) 1.74
Prednisone side-effects and serum-protein levels. A collaborative study. Lancet (1971) 1.67
Contribution of cigarette smoking to cadmium accumulation in man. Lancet (1972) 1.63
Enhanced biotransformation of theophylline in marihuana and tobacco smokers. Clin Pharmacol Ther (1978) 1.59
Effect of smoking on theophylline disposition. Clin Pharmacol Ther (1976) 1.58
Factors affecting theophylline clearances: age, tobacco, marijuana, cirrhosis, congestive heart failure, obesity, oral contraceptives, benzodiazepines, barbiturates, and ethanol. J Pharm Sci (1979) 1.56
Accumulation pharmacokinetics of tobramycin. Antimicrob Agents Chemother (1978) 1.51
Effects of change in elimination on varous parameters of the two-compartment open model. J Pharm Sci (1972) 1.51
Gentamicin tissue accumulation and nephrotoxic reactions. JAMA (1978) 1.49
Renal clearance and tissue accumulation of gentamicin. Clin Pharmacol Ther (1977) 1.48
Fourth-generation model for corticosteroid pharmacodynamics: a model for methylprednisolone effects on receptor/gene-mediated glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. J Pharmacokinet Biopharm (1998) 1.43
Development of translational pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther (2008) 1.42
Theophylline disposition in obesity. Clin Pharmacol Ther (1978) 1.42
Characterization of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm (1996) 1.38
Pharmacodynamic modeling of time-dependent transduction systems. Clin Pharmacol Ther (2001) 1.38
Comparison of ampicillin and hetacillin pharmacokinetics in man. J Pharm Sci (1973) 1.35
Theophylline secretion into breast milk. Pediatrics (1976) 1.35
Precursor-dependent indirect pharmacodynamic response model for tolerance and rebound phenomena. J Pharm Sci (1998) 1.34
Theophylline pharmacokinetics in premature infants with apnea. J Pediatr (1976) 1.34
Pharmacokinetics and pharmacodynamic modeling of direct suppression effects of methylprednisolone on serum cortisol and blood histamine in human subjects. Clin Pharmacol Ther (1989) 1.32
Pharmacokinetic/Pharmacodynamic models for corticosteroid receptor down-regulation and glutamine synthetase induction in rat skeletal muscle by a Receptor/Gene-mediated mechanism. J Pharmacol Exp Ther (1999) 1.27
Cadmium accumulation im man: influence of smoking, occupation, alcoholic habit and disease. J Chronic Dis (1972) 1.27
Transit compartments versus gamma distribution function to model signal transduction processes in pharmacodynamics. J Pharm Sci (1998) 1.26
Influence of cigarette smoking on drug metabolism in man. Drug Metab Rev (1979) 1.23
Plasma and tissue protein binding of drugs in pharmacokinetics. Drug Metab Rev (1976) 1.22
Analysis of methylprednisolone, methylprednisone and corticosterone for assessment of methylprednisolone disposition in the rat. J Chromatogr (1988) 1.22
Mathematical modeling of circadian cortisol concentrations using indirect response models: comparison of several methods. J Pharmacokinet Biopharm (1999) 1.22
Urinary casts as an indicator of renal tubular damage in patients receiving aminoglycosides. Antimicrob Agents Chemother (1979) 1.21
Pharmacodynamics of chemotherapeutic effects: dose-time-response relationships for phase-nonspecific agents. J Pharm Sci (1971) 1.19
Fluid shifts and other factors affecting plasma protein binding of prednisolone by equilibrium dialysis. J Pharm Sci (1984) 1.18
Ocular absorption of topically applied FK506 from liposomal and oil formulations in the rabbit eye. Invest Ophthalmol Vis Sci (1993) 1.17
Dose-dependence and repeated-dose studies for receptor/gene-mediated pharmacodynamics of methylprednisolone on glucocorticoid receptor down-regulation and tyrosine aminotransferase induction in rat liver. J Pharmacokinet Biopharm (1998) 1.17
Basic pharmacodynamic models for agents that alter production of natural cells. J Pharmacokinet Biopharm (1999) 1.17
Role of tobacco smoking in pharmacokinetics. J Pharmacokinet Biopharm (1978) 1.16
Pharmacokinetics of aztreonam in patients with gram-negative infections. Antimicrob Agents Chemother (1985) 1.15
Digoxin pharmacokinetics: role of renal failure in dosage regimen design. Clin Pharmacol Ther (1975) 1.11
Pharmacokinetics of methicillin in patients with cystic fibrosis. J Infect Dis (1977) 1.10
Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics. Clin Pharmacol Ther (1993) 1.10
Fluorometric analysis of ampicillin in biological fluids. J Pharm Sci (1971) 1.09
Enhanced renal excretion of dicloxacillin in patients with cystic fibrosis. Pediatrics (1975) 1.09
Receptor-mediated pharmacodynamics of prednisolone in the rat. J Pharmacokinet Biopharm (1986) 1.09
Algorithm for application of Fourier analysis for biorhythmic baselines of pharmacodynamic indirect response models. Chronobiol Int (2000) 1.07
Intravenous theophylline therapy: nomogram guidelines. Ann Intern Med (1977) 1.07
Precipitation of diazepam from intravenous preparations. JAMA (1973) 1.07
Pharmacokinetics of theophylline in hepatic disease. Chest (1978) 1.07
Pharmacoimmunodynamics of methylprednisolone: trafficking of helper T lymphocytes. J Pharmacokinet Biopharm (1992) 1.07
Early detection of aminoglycoside nephrotoxicity with urinary beta-2-microglobulin. J Med (1978) 1.05
Dose-dependent pharmacokinetics of mezlocillin in relation to renal impairment. Antimicrob Agents Chemother (1982) 1.05
Corticosteroid analysis in biological fluids by high-performance liquid chromatography. J Chromatogr (1979) 1.04
Pharmacokinetics of single and multiple doses of ethinyl estradiol and levonorgestrel in relation to smoking. Clin Pharmacol Ther (1988) 1.04
Dose dependent pharmacokinetics of prednisone and prednisolone in man. J Pharmacokinet Biopharm (1981) 1.03
Two-compartment basophil cell trafficking model for methylprednisolone pharmacodynamics. J Pharmacokinet Biopharm (1991) 1.03
Pharmacodynamic model for joint exogenous and endogenous corticosteroid suppression of lymphocyte trafficking. J Pharmacokinet Biopharm (1994) 1.02
Clinical pharmacokinetics and pharmacodynamics of a new squalene synthase inhibitor, BMS-188494, in healthy volunteers. J Clin Pharmacol (1998) 1.01
Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. J Clin Pharmacol (1992) 1.00
Nonlinear assessment of phenytoin bioavailability. J Pharmacokinet Biopharm (1976) 0.99
Active metabolites of imipramine and desipramine in man. Clin Pharmacol Ther (1982) 0.99
Pharmacokinetics of cyclophosphamide in man. Br J Pharmacol (1971) 0.99
Role of baseline parameters in determining indirect pharmacodynamic responses. J Pharm Sci (1999) 0.99
Molar quantification of specific messenger ribonucleic acid expression in northern hybridization using cRNA standards. Anal Biochem (1993) 0.98
Pharmacokinetics of methylprednisolone sodium succinate and methylprednisolone in patients undergoing cardiopulmonary bypass. Pharmacotherapy (1990) 0.98
Pharmacokinetics of digoxin in normal subjects after intravenous bolus and infusion doses. J Pharmacokinet Biopharm (1975) 0.98
Population pharmacokinetics of sirolimus in kidney transplant patients. Clin Pharmacol Ther (1997) 0.98
Pharmacokinetics of antibiotic absorption in coeliac disease. J Antimicrob Chemother (1976) 0.97
Modeling of dose-response-time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles. Biopharm Drug Dispos (2000) 0.97
Prednisolone disposition and protein binding in oral contraceptive users. J Clin Endocrinol Metab (1983) 0.97
Corticosteroid pharmacodynamic modeling: osteocalcin suppression by prednisolone. Pharm Res (1992) 0.97
Monitoring prednisone and prednisolone. Ther Drug Monit (1980) 0.97
Comparative tissue accumulation of gentamicin and tobramycin in patients. J Antimicrob Chemother (1978) 0.96
Third-generation model for corticosteroid pharmacodynamics: roles of glucocorticoid receptor mRNA and tyrosine aminotransferase mRNA in rat liver. J Pharmacokinet Biopharm (1995) 0.96
Effects of ketoconazole on methylprednisolone pharmacokinetics and cortisol secretion. Clin Pharmacol Ther (1986) 0.96
Estimation of oral bioavailability of a long half-life drug in healthy subjects. Pharm Res (1998) 0.96
Pharmacokinetics in the infant. Environ Health Perspect (1994) 0.95
Dosage regimen design. Pharmacol Ther (1982) 0.95
Species- and gender-related differences in cyclosporine/prednisolone/sirolimus interactions in whole blood lymphocyte proliferation assays. J Pharmacol Exp Ther (1998) 0.95
Pharmacokinetics and pharmacodynamics of methylprednisolone in obesity. Clin Pharmacol Ther (1991) 0.95
Partial pharmacodynamic model for the circadian-episodic secretion of cortisol in man. J Clin Endocrinol Metab (1975) 0.95
Dose-dependent disposition of oral propranolol in normal subjects. Biopharm Drug Dispos (1981) 0.95
Prednisolone pharmacokinetics and pharmacodynamics in relation to sex and race. J Clin Pharmacol (2001) 0.94
Prednisolone binding to albumin and transcortin in the presence of cortisol. Biochem Pharmacol (1982) 0.94
High-performance liquid chromatographic assay for imipramine, desipramine, and their 2-hydroxylated metabolites. J Pharm Sci (1979) 0.94
Developing compliance instructions for drug labeling. Clin Pharmacol Ther (2000) 0.94
Pharmacokinetic design of digoxin dosage regimens in relation to renal function. J Clin Pharmacol (1974) 0.94
Myocardial distribution of digoxin and renal function. Clin Pharmacol Ther (1974) 0.94
Gentamicin persistence in the body. Lancet (1977) 0.94
Modeling and allometric scaling of s(+)-ketoprofen pharmacokinetics and pharmacodynamics: a retrospective analysis. J Vet Pharmacol Ther (2004) 0.93
Lack of pharmacokinetic and pharmacodynamic interactions between ketoconazole and prednisolone. Clin Pharmacol Ther (1991) 0.92
Corticosteroid effects in skeletal muscle: gene induction/receptor autoregulation. Muscle Nerve (1997) 0.92
Phenobarbital effects on cyclophosphamide pharmacokinetics in man. Cancer Res (1972) 0.92
Pharmacodynamic modeling of prednisolone effects on natural killer cell trafficking. Pharm Res (1995) 0.92
Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys. J Pharmacol Exp Ther (2000) 0.92
Methylprednisolone versus prednisolone pharmacokinetics in relation to dose in adults. Eur J Clin Pharmacol (1986) 0.92
Integrated functions for four basic models of indirect pharmacodynamic response. J Pharm Sci (1998) 0.92
Breast milk distribution of theobromine from chocolate. J Pediatr (1977) 0.91